BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology firm focused on developing innovative immunotherapies for cancer, has announced its participation in the upcoming 40th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer (SITC), scheduled for November 5-9, 2025, in National Harbor, Maryland. The company will present a late-breaking update concerning clinical immunogenicity data from its ongoing Phase 2 AMPLIFY-7P trial of ELI-002, targeted at patients with mKRAS-driven pancreatic cancer, alongside preclinical findings related to ELI-004 for advanced solid tumors.
Presentation Details:
- Late-breaking Abstract (LBA) Poster Presentation
Title: AMPLIFY-7P Phase 2: T cell responses induced by ELI-002 7P, a lymph node-targeted amphiphile therapeutic cancer vaccine in patients with KRAS mutated pancreatic ductal adenocarcinoma
Presenter: Lisa McNeil, Ph.D., Vice President, Translational Medicine at Elicio
Abstract Number: 1317
Session Date: Friday, Nov. 7, 2025
Location: Prince George ABC Exhibit Halls – Gaylord National Resort and Convention - Poster Presentation
Title: Amphiphile (AMP)-Immunomodulator therapy controls growth and eradicates syngeneic solid tumors
Presenter: Martin Steinbuck, Ph.D., Director of Research at Elicio
Abstract Number: 946
Session Date: Saturday, Nov. 8, 2025
Location: Prince George ABC Exhibit Halls – Gaylord National Resort and Convention
About Elicio Therapeutics
Elicio Therapeutics, Inc. is dedicated to advancing novel immunotherapy solutions for prevalent cancers, specifically targeting mKRAS-positive pancreatic and colorectal cancers. The company aims to leverage recent advancements in personalized cancer immunotherapy to create effective off-the-shelf treatments. Its proprietary Amphiphile (AMP) technology is designed to enhance the education, activation, and amplification of cancer-specific T cells, promoting sustained cancer immunosurveillance in patients.
Currently, ELI-002 is being evaluated in a randomized clinical trial for patients with high-risk mKRAS-positive pancreatic cancer who have completed standard therapy. The drug has also undergone Phase 1 studies in patients with mKRAS-positive colorectal cancer. Notably, updated Phase 1 data for both pancreatic and colorectal cancer presented at the ESMO Immuno-Oncology Congress 2024 indicated a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months for the entire study population.
About ELI-002
ELI-002 is an investigational AMP cancer immunotherapy that targets cancers linked to mutations in the KRAS gene, a common driver in various human malignancies. This treatment comprises AMP-modified mutant KRAS peptide antigens paired with ELI-004, an AMP-modified immune-stimulatory CpG oligodeoxynucleotide, facilitating subcutaneous administration. The 2-peptide formulation of ELI-002 has been tested in a Phase 1 trial for patients at high risk of relapse post-surgery and chemotherapy, while the 7-peptide formulation is currently being investigated in the ongoing AMPLIFY-7P trial.
About ELI-004
ELI-004 is a novel AMP-modified immune-stimulatory CpG oligonucleotide that activates innate immune cells and promotes the production of essential inflammatory molecules to enhance immunity. Its design encourages targeted immune responses against tumors by facilitating localized delivery and retention within the lymph nodes.
About the Amphiphile Platform
Elicio”s AMP platform focuses on delivering immunotherapeutics directly to lymph nodes, aiming to enhance immune education and activation. This targeted approach has shown promise in preclinical models, suggesting greater therapeutic efficacy compared to traditional immunotherapies that do not engage lymph nodes.
For further details, visit www.elicio.com.
Cautionary Note on Forward-Looking Statements
Certain statements in this communication are forward-looking and involve risks that may cause actual results to differ. Elicio does not undertake any obligation to update these forward-looking statements except as required by law.
Investor Relations Contact:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
[email protected]
